Clinical Trial Categories
Ovarian Trials
Trial ID ESR 22-21698 (EIMPRIS)
NCT05438498clinicaltrials.gov ID
Phase II/III
Trial ID 18194
nct 03748186clinicaltrials.gov ID
USOR ID: 18194
Phase I
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Trial ID 20289
NCT04254107clinicaltrials.gov ID
USOR ID: 20289
Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Trial ID 20298
NCT04625270clinicaltrials.gov ID
USOR ID: 20298
Phase II
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer
Trial ID 20156
NCT04729387clinicaltrials.gov ID
USOR ID: 20156
Phase III
A Phase III randomized study to assess the efficacy and safety of alpelisib(BYL719) in combination with olaparib in patients with BRCA wild-type, platinum-resistant or refractory high grade serous ovarian cancer.
